Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab subcutaneous plus DMARDs versus placebo plus DMARDs in moderate to severe active rheumatoid arthritis
2010-019912-18Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab SC + traditional DMARDs with Placebo SC + traditional DMARDs (2 arms). Primary endpoint: ACR20 response at Week 24. Started Jan 2011; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-019912-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019912-18.